Boothbay Fund Management’s Theriva Biologics TOVX Stock Holding History

Boothbay Fund Management’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.92K	Hold	27,646	–	–	﹤0.01%	2192
2026 Q1	$5.41K	Hold	27,646	–	–	﹤0.01%	2006
2025 Q4	$5.82K	Sell	27,646 -7,955	-22%	-$2.35K	﹤0.01%	1907
2025 Q3	$14.4K	Hold	35,601	–	–	﹤0.01%	1826
2025 Q2	$15.4K	Hold	35,601	–	–	﹤0.01%	1395
2025 Q1	$39.2K	Buy	+35,601	New	+$49.8K	﹤0.01%	1300
2020 Q3	–	Sell	-225	Closed	-$29K	–	1221
2020 Q2	$29K	Hold	225	–	–	﹤0.01%	932
2020 Q1	$18K	Sell	225 -15	-6%	-$1.71K	﹤0.01%	811
2019 Q4	$30K	Hold	240	–	–	﹤0.01%	814
2019 Q3	$27K	Hold	240	–	–	﹤0.01%	737
2019 Q2	$33K	Hold	240	–	–	﹤0.01%	693
2019 Q1	$41K	Hold	240	–	–	﹤0.01%	710
2018 Q4	$34K	Buy	+240	New	+$57K	0.01%	604

Other funds holding TOVX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Boothbay Fund Management's TOVX Position: Q2 2026 in Review

Boothbay Fund Management held its Theriva Biologics (TOVX) position steady in Q2 2026 at 27,646 shares worth $6.92K. The position accounts for ﹤0.01% of the portfolio, ranked #2192.

Boothbay Fund Management first reported a position in TOVX in Q4 2018 and has held it in 13 quarters since. The position peaked at $41K in Q1 2019. 26 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.

Boothbay Fund Management held 27,646 shares of Theriva Biologics worth $6.92K as of Q2 2026.
Boothbay Fund Management left its Theriva Biologics share count unchanged in Q2 2026.
Theriva Biologics made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #2192 holding.
Boothbay Fund Management first reported a position in Theriva Biologics in Q4 2018 and has held it in 13 quarters since.
Boothbay Fund Management's Theriva Biologics position peaked at $41K in Q1 2019.
26 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.